Dienstag, 17. Januar 2017


  • Pressemitteilung BoxID 542946

Oxford Immunotec Announces First Patient Enrolled in REACT Trial for T-SPOT.CMV

(lifePR) (OXFORD, United Kingdom and MARLBOROUGH, Mass, ) Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the first patient has been enrolled in the REACT study. The REACT study, which focuses on stem cell transplant patients, is the second of two pivotal clinical trials designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV test.

"We are happy to announce that the enrollment process is underway, on schedule, for our REACT study," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We remain excited about the potential clinical and economic value of our T-SPOT.CMV test."

About the T-SPOT.CMV test

Our T-SPOT.CMV test measures the strength of T cell responses to Cytomegalovirus (CMV) to assess susceptibility to CMV infection. CMV disease is a common and serious complication in both solid organ and stem cell transplantation. Our T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform.

Oxford Immunotec Inc.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company's second product and the first in a series of products intended for the transplantation market. The Company has six additional active development programs, each of which leverages our T cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Diese Pressemitteilungen könnten Sie auch interessieren

BGM - Burn out Prohylaxe

, Gesundheit & Medizin, Klinik Prof. Schedel GmbH

Betriebliches Gesundheitsmanagemen­t wird in der Klinik Prof. Schedel groß geschrieben. Die Zufriedenheit der Mitarbeiter steht für die Geschäftsleitung...

Heute wird gekuschelt!

, Gesundheit & Medizin, Ofa Bamberg GmbH

Am 21. Januar ist Weltkuscheltag! Der passende Zeitpunkt, um es sich drinnen einmal so richtig gemütlich zu machen, während draußen winterliche...

Aktiv mit Multipler Sklerose

, Gesundheit & Medizin, AMSEL e.V., Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg e.V.

Am Freitag, den 3. Februar, lädt AMSEL e.V. gemeinsam mit den AMSEL-Kontaktgruppen Göppingen und Wernau ab 14.30 Uhr zum Fachvortrag "Aktiv mit...

Disclaimer